Clinical trials: Insufficient Metabolic Control
Type 2 Diabetes Mellitus
Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)
A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes
- Trial name
- NCT00449930
- Testing
- sitagliptin phosphate, Comparator: metformin hydrochloride
- Volunteers
- 1,050 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled…
- Trial name
- NCT00095030
- Testing
- muraglitazar
- Where
- 206 sites in United States, Argentina and 15 more
- Volunteers
- 1,752 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)
This is a clinical study to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00289848
- Testing
- sitagliptin phosphate
- Volunteers
- 530 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes
The purpose of this study is to compare Muraglitazar and Pioglitazone in patients with Type 2 Diabetes. Both the safety and blood sugar lowering effects of these treatments will be studied.
- Trial name
- NCT00106808
- Testing
- Muraglitazar, Pioglitazone
- Where
- 195 sites in United States, Argentina and 12 more
- Volunteers
- 1,440 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus, Inadequate Glucose Control
Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie
Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie
- Trial name
- NCT03770052
- Testing
- duvie
- Where
- South Korea
- Volunteers
- 159 people
- Sponsor
- Pusan National University Hospital
Type 2 Diabetes Mellitus
Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM
This study was designed as a non-interventional, single-group, open-label, multicenter observational study for patients with type 2 diabetes in the real world clinical setting.
- Trial name
- SSUG (NCT04267601)
- Testing
- Anagliptin
- Where
- South Korea
- Volunteers
- 2,448 people
- Sponsor
- JW Pharmaceutical
Type 2 Diabetes
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
Failure of oral antidiabetic drugs (OADs) is a frequent challenge in patients with type 2 diabetes mellitus (T2DM), and inadequate long-term glycemic control substantially increases the risk of diabetic complications.
- Trial name
- NCT07173712
- Testing
- CSII, Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin Degludec and Insulin Aspart Injection
- Volunteers
- 324 people
- Sponsor
- Yanbing Li
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.
- Trial name
- NCT01422876
- Testing
- high dose FDC, BI 10773 high dose
- Where
- 211 sites in United States, Argentina and 20 more
- Volunteers
- 1,405 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes
This study is being carried out to see if dapagliflozin in addition to metformin decreases body weight and if so, how it compares with metformin alone.
- Trial name
- NCT00855166
- Testing
- Dapagliflozin, Metformin, Sitagliptin
- Where
- 21 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 182 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise
The aim of this trial is to evaluate the efficacy and safety of HRS-7535 compared with placebo in subjects with type 2 diabetes mellitus with inadequate glycemic control with diet and exercise
- Trial name
- OUTSTAND-1 (NCT06672172)
- Testing
- HRS-7535 tablet
- Where
- China
- Volunteers
- 284 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Primary Objective: To demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1C (HbA1c) reduction in participants with type 2 diabetes mellitus (T2D) who have inadequate…
- Trial name
- SOTA-INS (NCT03285594)
- Testing
- Sotagliflozin, Insulin glargine (HOE901), Oral Antidiabetes Drugs (OADs)
- Where
- 106 sites in United States, Bulgaria and 6 more
- Volunteers
- 571 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus, Type 2
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients…
- Trial name
- NCT01159600
- Testing
- BI 10773
- Where
- 148 sites in United States, Canada and 10 more
- Volunteers
- 1,504 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM
A multicenter, randomized, double blind, placebo controlled, parallel, phase Ⅲ study to evaluate the efficacy and safety of JW0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202…
- Trial name
- NCT05814406
- Testing
- JW0201
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- JW Pharmaceutical
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
This study will examine the safety and efficacy of the addition of omarigliptin in Japanese participants with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent…
- Trial name
- NCT01697592
- Testing
- Omarigliptin
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
T2DM (Type 2 Diabetes Mellitus)
A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus
This is a four-way (Participant, Care Provider, Investigator, Outcomes Assessor) masked (blinded) study designed to explore the efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks in…
- Trial name
- NCT03467932
- Testing
- Cohort A: ORMD-0801, Cohort B: ORMD-0801
- Where
- United States
- Volunteers
- 373 people
- Sponsor
- Oramed, Ltd.
Diabetes Mellitus
A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322
To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.
- Trial name
- NCT01686711
- Testing
- AD-4833 15 mg, AD-4833 30 mg
- Where
- 25 sites in Japan
- Volunteers
- 207 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)
The purpose of this study is to examine the safety and tolerability of sitagliptin 100 mg/simvastatin 40 mg FDC (MK-0431D) in Vietnamese participants with type 2 diabetes mellitus with inadequate glycemic control on metformin.
- Trial name
- NCT01702298
- Testing
- Sitagliptin 100 mg/simvastatin 40 mg FDC, Metformin
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in…
- Trial name
- NCT02284893
- Testing
- Saxagliptin, Dapagliflozin, Sitagliptin
- Where
- 79 sites in United States, Hungary and 4 more
- Volunteers
- 461 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type II
A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)
A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.
- Trial name
- NCT00482079
- Testing
- MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks
- Volunteers
- 743 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult Indian patients with inadequate glycaemic control with diet and…
- Trial name
- NCT00918879
- Testing
- Saxagliptin
- Where
- 9 sites in India
- Volunteers
- 213 people
- Sponsor
- AstraZeneca